new NSAID specifically targets her2+ breast cancer by decreasing her2 receptor trans-

[Lani]

cription

Mol Cancer Ther. 2009 May 12. [Epub ahead of print]

The nonsteroidal anti-inflammatory drug tolfenamic acid inhibits BT474 and SKBR3 breast cancer cell and tumor growth by repressing erbB2 expression.

Liu X, Abdelrahim M, Abudayyeh A, Lei P, Safe S.
Departments of 1Biochemistry and Biophysics and 2Veterinary Physiology and Pharmacology, Texas A&M University, College Station, Texas; 3Cancer Research Institute, M. D. Anderson Cancer Center, Orlando Regional Health, Care, Orlando, Florida; and 4Department of Internal Medicine, Baylor College of Medicine, One Baylor Plaza and 5Institute of Biosciences and Technology, Texas A&M University Health Science Center, Houston, Texas.
Tolfenamic acid (TA) is a nonsteroidal anti-inflammatory drug that inhibits pancreatic cancer cell and tumor growth through decreasing expression of specificity protein (Sp) transcription factors. TA also inhibits growth of erbB2-overexpressing BT474 and SKBR3 breast cancer cells; however, in contrast to pancreatic cancer cells, TA induced down-regulation of erbB2 but not Sp proteins. TA-induced erbB2 down-regulation was accompanied by decreased erbB2-dependent kinase activities, induction of p27, and decreased expression of cyclin D1. TA also decreased erbB2 mRNA expression and promoter activity, and this was due to decreased mRNA stability in BT474 cells and, in both cell lines, TA decreased expression of the YY1 and AP-2 transcription factors required for basal erbB2 expression. In addition, TA also inhibited tumor growth in athymic nude mice in which BT474 cells were injected into the mammary fat pad. TA represents a novel and promising new anticancer drug that targets erbB2 by decreasing transcription of this oncogene. [Mol Cancer Ther 2009;8(5):1207-17].
PMID: 19435870

[Ellie F]

Hi, my friend gets this on prescription and takes this for migraines.
Can't remember where I saw it but ibuprofen was also supposed to impact on her2 as it is a COX inhibitor. Wonder if this means that we will soon be prescibed low doses of these drugs as part of the battle to reduce spread?
Ellie

[Rich66]

related:
1: Carcinogenesis. (javascript:AL_get(this,%20'jour',%20'Carcinogenes is.');) 2009 Apr 30. [Epub ahead of print]http://www.ncbi.nlm.nih.gov/corehtml/query/egifs/http:--highwire.stanford.edu-icons-externalservices-pubmed-custom-oxfordjournals_aop.gif (http://www.ncbi.nlm.nih.gov/entrez/utils/fref.fcgi?PrId=3051&itool=AbstractPlus-def&uid=19406933&db=pubmed&url=http://carcin.oxfordjournals.org/cgi/pmidlookup?view=long&pmid=19406933) Links (javascript:PopUpMenu2_Set(Menu19406933);)
Tolfenamic Acid Inhibits Esophageal Cancer Through Repression of Specificity Proteins and c-Met.

Papineni S (http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Papineni%20S%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsP anel.Pubmed_DiscoveryPanel.Pubmed_RVAbstractPlus), Chintharlapalli S (http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Chintharlapalli%20S%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsP anel.Pubmed_DiscoveryPanel.Pubmed_RVAbstractPlus), Abdelrahim M (http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Abdelrahim%20M%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsP anel.Pubmed_DiscoveryPanel.Pubmed_RVAbstractPlus), Lee SO (http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Lee%20SO%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsP anel.Pubmed_DiscoveryPanel.Pubmed_RVAbstractPlus), Burghardt R (http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Burghardt%20R%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsP anel.Pubmed_DiscoveryPanel.Pubmed_RVAbstractPlus), Abudayyeh A (http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Abudayyeh%20A%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsP anel.Pubmed_DiscoveryPanel.Pubmed_RVAbstractPlus), Baker C (http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Baker%20C%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsP anel.Pubmed_DiscoveryPanel.Pubmed_RVAbstractPlus), Herrera L (http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Herrera%20L%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsP anel.Pubmed_DiscoveryPanel.Pubmed_RVAbstractPlus), Safe S (http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Safe%20S%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsP anel.Pubmed_DiscoveryPanel.Pubmed_RVAbstractPlus).
Department of Veterinary Physiology and Pharmacology, Texas A&M University, College Station, TX 77843-4466.
The nonsteroidal anti-inflammatory drug (NSAID) tolfenamic acid inhibits proliferation of SEG-1 and BIC-1 esophageal cancer cells with IC(50) values of 36 and 48 muM, respectively. TA also increased Annexin V staining in both cell lines, indicative of proapoptotic activity. Treatment of SEG-1 and BIC-1 cells with TA for up to 72 hr decreased expression of specificity protein (Sp) transcription factors Sp1, Sp3 and Sp4 and this was accompanied by decreased expression of the well characterized Sp-regulated genes cyclin D1, vascular endothelial growth factor (VEGF) and survivin. TA also decreased hepatocyte growth factor receptor, c-Met, a receptor tyrosine kinase that is overexpressed in esophageal cancer cells and tumors and is an important drug target. Knockdown of Sp1, Sp3 and Sp4 by RNA interference in SEG-1 and BIC-1 cells also decreased c-Met expression, demonstrating that c-Met is an Sp-regulated gene in esophageal cancer cells. Sp1 was overexpressed in esophageal cancer cells and tumors and increased Sp1 staining was observed in esophageal tumors from patients. TA (20 mg/kg/d) also decreased tumor growth and weight in athymic nude mice bearing SEG-1 cells as xenografts and this was accompanied by increased apoptosis and decreased Sp1 and c-Met staining in tumors from treated mice. Thus, TA-dependent downregulation of Sp transcription factors and c-Met defines a novel chemotherapeutic approach for treatment of esophageal cancer.

[SoCalGal]

I have taken Advil for a million years. Maybe that's why I'm still here? Of course, for the last year it's been a no-no with the Avastin. Hmmmm.

[Rich66]

A million years? I'll have what she's having;)

[Brenda_D]

I've been on the NSAID Volteran (diclofenac) for at least 5 five years for inflammation. During that period I got her2 positive BC.
I'll have to ask my new onc about this new drug.

[Rich66]

Brenda D,
An alert on Diclofenac
http://www.medscape.com/viewarticle/713451

[Adriana Mangus]

Dear Lani;

I do believe the report.

My lovely mother, she will be 87 in June is healthy as a horse. She's been taking anti-inflamatory meds for at least the last 50 years. She constantly complains of aches and pains.

I suspect she suffers from fibromyalgia-- I do,-- but she refuses to believe that, and living in Mexico all of her life there was not a tool or a doctor that would/could have help.

She was dx however with a small tiny tumor in the cervix , it was removed and she continued with her OTC meds.

I'm the youngest and the only one with BC, it's important to mention that am also the only one in the family who does not like to take any type of pain killers, even for fibromyalgia. I do practice yoga when the pain is too much to take.

I will open a bottle right now and start taking Ibuprofen, it won't hurt me and perhaps it will keep the mets at bay. I hope.

Love,

Adriana

[Ellie F]

may be the way forward with these nsai drugs is the metronomic approach, taking maybe one tablet each day. Seems like that may keep the beast down but not do too much damage.Just a thought1
Ellie